Purpose: The COMRADE studies are the first randomized controlled head-to-head trials comparing the efficacy and safety of intravitreal ranibizumab versus dexamethasone (DEX) in patients with macular oedema secondary to retinal vein occlusion (RVO). The COMRADE extension trial was designed to provide additional 6-month data of patients who completed the core studies.
Introduction
Retinal vein occlusion (RVO) is a common retinal vascular disorder and occurs as central RVO (CRVO) or, more commonly, branch RVO (BRVO) (Kolar 2014) . These types differ in their characteristics, but leakage of blood and fluid from the blocked retinal vein can lead to macular oedema and vision loss in both forms.
Ranibizumab (Lucentis Ò ; Novartis Pharma AG, Basel, Switzerland, and Genentech Inc., South San Francisco, CA, USA) (EMA 2014) and the slowrelease dexamethasone implant (DEX implant; Ozurdex Ò ; Allergan Inc., Irvine, CA, USA, and Allergan Pharmaceuticals, Dublin, Ireland) (EMA 2010) are both approved for the treatment of macular oedema secondary to RVO. A number of international expert panel reports have been published comparing these drugs (Berger et al. 2015; Sivaprasad et al. 2015; Pulido et al. 2016) . In this context, it has been repeatedly debated whether the higher number of ranibizumab injections or the known side effects of DEX [cataract and increased intraocular pressure (IOP)] should be regarded as the more disadvantageous (Pielen et al. 2013; Reid et al. 2015) . The two COMRADE core trials, conducted from 2011 to 2014, were the first head-to-head comparisons of ranibizumab and DEX in patients presenting visual impairment due to macular oedema secondary to BRVO (COM-RADE-B) (Hattenbach et al. 2018 ) and CRVO (COMRADE-C) (Hoerauf et al. 2016 ). Both were 6-month, phase IIIb, multicentre, randomized, double-masked studies comparing the safety and efficacy of ranibizumab injections versus DEX implants, following the European labels (EMA 2010 (EMA , 2014 .
For both BRVO and CRVO, the COMRADE studies indicated that ranibizumab injections according to a pro re nata (PRN; as needed) schedule were more effective than a single DEX implant from month 3 to month 6 in patients with macular oedema. The primary analyses showed significantly better visual outcomes for ranibizumab at 6 months in both indications. The incidence of ocular treatment-emergent adverse events (TEAEs) and of increases in IOP was higher with DEX than with ranibizumab (Hoerauf et al. 2016; Hattenbach et al. 2018) .
To obtain results over 12 months, especially regarding TEAEs, best-corrected visual acuity (BCVA), and the number of injections required to achieve good outcomes, we conducted a 6-month extension to the COMRADE core studies. Safety and efficacy of ranibizumab and DEX were assessed when used according to the European labels of both drugs (EMA 2010 (EMA , 2014 .
Materials and Methods

Study design
The COMRADE extension study was an open-label, multicentre, 6-month, phase IV study comparing the safety and efficacy of ranibizumab injections and DEX implants for BRVO and CRVO based on the European labels of both drugs (EMA 2010 (EMA , 2014 . Our assessments and analyses did not differ from the core studies (details published previously (Hoerauf et al. 2016; Hattenbach et al. 2018) ). Key methods specific to the extension study are described below.
The study protocol was reviewed and approved by an independent ethics committee and has followed the Tenets of the Declaration of Helsinki. The study was registered on www.clinica ltrials.gov (ID: NCT01580020). It was conducted at 37 sites in Germany from 2012 to 2014.
Patients and treatments
Only patients at German COMRADE study sites who had completed the core COMRADE study and provided written informed consent were enrolled (Fig. 1) . All patients remained in the same treatment group that they had been randomized to for the core studies. Patients in the ranibizumab group received injections of 0.5 mg ranibizumab according to an 'on-label' PRN scheme: when monthly monitoring indicated a loss of visual acuity (VA) due to disease activity, monthly injections were resumed until stable VA was reached for three consecutive months. Patients in the DEX group were also monitored monthly and treated according to a PRN scheme. Patients could receive a 0.7 mg DEX implant at the start of the extension or later, if a decline from stable VA due to disease activity was detected and if retreatment was deemed beneficial in the investigator's opinion. A minimum 5-month period between implantations was required, as a shorter interval was suspected to lead to more complications (Mathew et al. 2014) . Seven study visits were scheduled during the 6-month extension.
Objectives
Our main objective was to descriptively evaluate ocular and nonocular TEAE during the 6-month extension. Further objectives included the analysis of visual outcomes. Our extension results were combined and compared with the core COMRADE study's results.
Outcome assessments
Safety during the extension was evaluated by analysing TEAEs, as well as by ophthalmic examinations including tonometry. As in the core studies, further key assessments included BCVA measurements [Early Treatment Diabetic Retinopathy Study (ETDRS)-like chart at 4 metres) and optical coherence tomography (OCT) at each visit. An independent review of the OCT images was performed at the central reading centre (GRADE, University of Bonn, Germany).
Statistical analyses
We merged our extension results with the core study data (from patients who continued into the extension) and processed them analogously to the core studies, taking into account the differences in objectives. The extension study's focus was on safety (based on the safety set); all efficacy analyses were exploratory and based on the full analysis set (FAS). The safety set included all patients from the safety sets of the core studies who had undergone at least one study treatment application and at least one safety assessment during the extension. The FAS included all patients from the FAS of the core studies who had at least one study treatment application and at least one postbaseline BCVA assessment during the extension. Especially regarding time course evaluations over 12 months, it is important to note that the results presented here only include the core study data from our extension population. No sample size considerations were required and the safety aspects were evaluated descriptively, as all patients at German sites who completed the core studies and wished to continue were enrolled.
The statistical analysis was performed analogously to the core studies (Hoerauf et al. 2016; Hattenbach et al. 2018) . All variables were analysed descriptively. Changes in BCVA were subjected to an analysis of covariance (ANCOVA) model. The last observation carried forward (LOCF) approach was used to account for missing data. (Figs 1, S1 ).
Results
Participants
Overall, 87 BRVO patients (94.6%) and 81 CRVO patients (97.6%) completed the extension. Discontinuations due to TEAE(s) were reported for one patient in each indication and treatment.
Demographic and baseline disease characteristics were similar between treatment groups at month 6 in both indications (extension baseline; see Table 1 ).
Treatment exposure
After the 'initial treatment phase' at the start of the core COMRADE studies, during which patients received at least three ranibizumab injections or a single DEX implant, treatments were carried out according to a PRN schedule. A minimum of 5 months was required between DEX implants; ranibizumab could be administered monthly.
Of the 52 BRVO patients treated with ranibizumab in the extension study, 50 patients (96.2%) received at least one reinjection (maximum: nine), while 16 of 40 patients (40.0%) treated with DEX received one retreatment. The mean [AEstandard deviation (SD)] cumulative number of injections from after the initial treatment phase (month 3 of core studies) until the end of the extension was 4.46 AE 2.09 for ranibizumab and 0.40 AE 0.50 for DEX. Among the CRVO patients in the extension study, 49 of 61 patients (80.3%) treated with ranibizumab and ten of 22 patients (45.5%) treated with DEX received at least one retreatment. The mean (AESD) cumulative number of injections from the end of the initial treatment phase until the end of the extension was 3.92 AE 2.64 for (Tables S1, S2 , and S3).
Safety
Evaluation of TEAEs was our primary objective in the extension study. This was based on the safety population (92 BRVO patients, 83 CRVO patients).
During the extension, in patients with BRVO, TEAEs of the study eye occurred in 55.8% of patients treated with ranibizumab and in 62.5% treated with DEX. Nonocular TEAEs occurred in 69.2% of ranibizumab patients and 47.5% of DEX patients.
In CRVO patients, TEAEs of the study eye were documented for 65.6% of ranibizumab patients and for 59.1% of DEX patients. Nonocular TEAEs occurred in 59.0% of patients treated with ranibizumab and in 59.1% treated with DEX. The only nonocular TEAEs that occurred in more than two patients per indication and treatment were nasopharyngitis, back pain, and cough, all of which occurred at a similar or higher frequency in the ranibizumab group than in the DEX group.
In BRVO patients, serious adverse events (SAEs) were reported for five patients [two ranibizumab patients (3.8%) and three DEX patients (7.5%)] and all were nonocular. In the CRVO indication, six patients (0.9%) treated with ranibizumab experienced SAEs, four (6.6%) of whom had SAEs in the study eye (iris neovascularisation, macular oedema, ocular ischaemic syndrome, reduced VA, vitreous haemorrhage), one (1.6%) had SAEs in both eyes (glaucoma), and two (3.3%) experienced nonocular SAEs. One (4.5%) DEX patient experienced ocular SAEs (retinal detachment, vitreous haemorrhage). No deaths occurred during the extension study. Table 1 . Patient characteristics at baseline of extension study (all enrolled patients).
Age (years) ¶ Mean AE SD 64.5 AE 9.7 64.6 AE 9.9 64.6 AE 9.7 66.6 AE 10.1 61.1 AE 11.0 65.1 AE 10.5 Median ( * Data for FCPT only available for 51 patients in this treatment group. † Data for FCPT only available for 39 patients in this treatment group. ‡ Data for BMI only available for 58 patients, for CSRT for 60 patients, and for FCPT for 59 patients in this treatment group. § Data for FCPT only available for 21 patients in this treatment group.
-Data for age and BMI were obtained at the screening visit of the core study. ** Data of the core study were used in case of discrepancies between core and extension study regarding race. In BRVO and CRVO, one patient was documented as 'Other' in the core study and as 'Caucasian' in the extension study. Additionally, for 1 CRVO patient it was vice versa. † † Data not available for 1 patient in the BRVO ranibizumab treatment group. ‡ ‡ Baseline values were the latest available values from baseline visit or screening visit.
In BRVO patients, the most frequent ocular TEAEs in the study eye were increased IOP, macular oedema, and ocular hyperaemia. We documented the most notable differences between treatment groups in conjunction with increased IOP, conjunctival haemorrhage, and cataract, which occurred more frequently in patients treated with DEX, as well as for macular oedema and eye pain, which occurred more frequently with ranibizumab. In CRVO, the most frequent events were macular oedema, eye pain, and reduced VA. Macular oedema and reduced VA were reported considerably more frequently for ranibizumab than DEX, while increased IOP was documented much more often for DEX than ranibizumab. Study drug-related TEAEs in the study eye occurred more often with DEX (seven patients, 31.8%) than with ranibizumab (three patients, 4.9%). The most frequent ocular TEAEs (study eye) during the extension are presented in Table 2 (for most frequent injectionrelated ocular TEAEs, see Table S4 ).
Intraocular pressure (IOP) increases in the study eye were observed throughout the extension, in both indications, and in conjunction with both therapies. While the mean IOP remained relatively low and constant over time for ranibizumab, the DEX patients' IOP exhibited broader fluctuations and higher peaks (Table S5) .
The incidence of increases in IOP of ≥21 mmHg was investigated over a 12-month period in a post hoc analysis. Such increases were reported more frequently for DEX [BRVO: 29 patients (72.5%); CRVO: 13 patients (59.1%)] than ranibizumab [BRVO: 7 patients (13.5%); CRVO: 16 patients (26.2%)], a difference that was statistically significant (BRVO: p < 0.001; CRVO: p = 0.009; Table S6 ).
A few cases of cataract were documented over the course of 12 months in both indications. Five patients (4.4%) treated with ranibizumab (two BRVO and three CRVO patients) and seven patients (11.3%) treated with DEX (six BRVO and one CRVO patients) presented clinically relevant cataract formation, a difference that was not statistically significant (Table S7) .
Efficacy
Mean BCVA (ETDRS letters) remained nearly constant throughout the extension study, for both drugs and in both indications, when treating patients in the regimen previously described. At month 12, the extension population reached raw mean (SD) BCVA changes of 22.2 (9.8) letters (ranibizumab) and 12.3 (13.4) letters (DEX) in BRVO and 18.9 (14.1) letters (ranibizumab) and 13.5 (21.3) letters (DEX) in CRVO ( Fig. 2 ; Table S8 ).
Evaluation of the mean average change in BCVA during the extension (mean change averaged over months 7-12) in relation to the core study baseline supported the efficacy of ranibizumab (Table S9 ). In BRVO patients, the change from core study baseline [adjusted least squares (LS) means] was 17.98 letters [95% confidence interval (CI), 15.01; 20.95] for ranibizumab and 13.13 letters (95% CI, 9.75; 16.50) for DEX. The difference (LS mean) between treatment groups was 4.85 letters (95% CI, 0.63; 9.07) and attained statistical significance (p = 0.0249). The CRVO results were consistent with those for Table 2 . Most frequent ocular adverse events (TEAEs) of the study eye during the extension study (safety set). SOCs and preferred terms within SOCs are presented in descending order of frequency in the total BRVO and CRVO populations. Table shows all TEAEs with an incidence of ≥5% in any group in any indication. BRVO = branch retinal vein occlusion, CRVO = central retinal vein occlusion, MedDRA = Medical Dictionary for Regulatory Activities, SOC = MedDRA system organ class, TEAE = treatment-emergent adverse event. * The preferred terms 'cataract subcapsular', 'cataract cortical', and 'cataract nuclear' were also reported during the extension; however, not in more than 1 patient per treatment group (see Table S15 ).
BRVO, although the difference between treatment groups of 5.37 letters (95% CI, À1.29; 12.03) was not statistically significant (p = 0.1119). Here, the change from core study baseline was 18.28 letters (95% CI, 14.73; 21.84) for ranibizumab and 12.92 letters (95% CI, 7.04; 18.80) for DEX. The results for the mean average change in BCVA from core study baseline to the end of the extension (mean change averaged over 12 months for the extension population) were similar for BRVO and CRVO (Table S10) . Here, the difference in LS means between treatment groups was 4.67 letters (95% CI, 0.77; 8.57; p = 0.0196) in BRVO patients and 5.37 letters (95% CI, À0.63; 11.36; p = 0.0784) in CRVO patients.
When assessing the BCVA results by month over the entire 12-month study period, the effect of treatment on mean BCVA was visible from month 3 of the core studies onwards, with greater improvement in BCVA for ranibizumab compared with DEX in both indications ( Fig. 2; Table S11 ). In accordance with the European label, only one DEX implant was permitted per 6 months in the core COMRADE studies (note that the aforementioned results are from the extension population). Visual acuity (VA) improvement was less pronounced in the entire core study population ( Fig. 2; Table S12 ).
When evaluating the results of all patients who continued into the extension, mean central subfield retinal thickness (CSRT) at core study baseline and its development over the course of 12 months was comparable between treatment groups in conjunction with both indications. The mean change from baseline to month 12 was notably higher for ranibizumab than DEX in BRVO patients. We observed a similar tendency in the CRVO patients, albeit with a smaller difference between therapies. Overall, the CSRT stayed more consistent for ranibizumab than DEX, also resembling what we had observed in the core study populations ( Fig. 3 ; Tables S13, S14, and S15).
Discussion
The COMRADE studies were the first prospective, randomized, head-to-head comparisons of ranibizumab and DEX for the treatment of macular oedema in BRVO (COMRADE-B) and CRVO (COMRADE-C). Both studies demonstrated a superior effect of ranibizumab over DEX with regard to visual outcome after 6 months when used according to the European labels (Hoerauf et al. 2016; Hattenbach et al. 2018) .
The current results confirm the findings from the COMRADE core studies for BRVO and CRVO. Patients who received continued treatment with ranibizumab after completing the core study period (COMRADE-B, COMRADE-C) exhibited a sustained improvement in BCVA until month 12, whereas in the DEX-treated patients who entered the extension trial at a lower BCVA level, mean BCVA improved during the first 2 months after retreatment with DEX, but declined thereafter. In addition, we observed greater fluctuation of mean CSRT in DEX-treated patients than in conjunction with ranibizumab over the entire study period. Previous studies have demonstrated that this factor is a typical feature of repeat DEX treatment in patients with RVO (Bandello et al. 2015) . However, while BRVO patients who underwent continued treatment with ranibizumab exhibited significantly better outcomes compared to DEX, this difference was no longer statistically significant by the end of the extension trial among patients with CRVO.
This observation may in part be explained by the higher than anticipated efficacy we noted in those DEX patients who elected to enrol in the extension trial. Compared to the overall core study population, CRVO and BRVO patients who entered the extension trial exhibited greater BCVA improvements from baseline to month 6, and this difference was even more pronounced among CRVO patients who received DEX (+11.7 letters). However, because this subset of patients was relatively small, we were not able to identify factors that may have contributed to their more favourable outcome.
Overall, treatment with ranibizumab or DEX in the COMRADE extension study yielded considerably better outcomes than in the pivotal ranibizumab trials after 12 months, i.e. BRAVO ) (18.3 letters versus BRVO 20.0 letters in COMRADE extension) and CRUISE (Campochiaro et al. 2011) (13.9 letters versus CRVO 18.9 letters in COMRADE extension), or the pivotal DEX trial GENEVA (Haller et al. 2011 ) (BRVÕ 7 letters versus 12.3 letters in COM-RADE extension; CRVO~2 letters versus 11.9 letters in COMRADE extension).
The current results, however, may not only be attributed to a positive selection bias. A particular feature of the COMRADE trials was our adherence to a treatment regimen according to the study drugs' European labels (EMA 2010 (EMA , 2014 . When the COM-RADE studies were designed, ranibizumab treatment consisted of initial monthly injections, followed by a PRN routine based on VA stability at three subsequent visits. This is more similar to the currently used treat-and-extend regimen than a rigid PRN protocol based on functional or morphological criteria. Thus, the COMRADE treatment regimen may have contributed to the favourable study results, indicating that close follow-ups and continuous treatment are essential for maintaining visual improvement in patients with RVO.
To date, the COMRADE core trials are the only published controlled headto-head studies of ranibizumab versus DEX in RVO. Only one similar study, the COMO trial sponsored by Allergan, attempted a controlled randomised head-to-head comparison of ranibizumab to DEX in BRVO. Available data (www.clinicaltrials.gov identifier: NCT01427751) (Allergan 2016) suggest that BRVO patients treated with ranibizumab (monthly injections over 5 months, PRN thereafter) revealed numerically lower nonserious TEAE incidence and better efficacy (BCVA, CSRT and VFQ-25 improvements) over 12 months than patients treated with DEX implants (injection at day 1 and month 5, one optional implant thereafter) (Allergan 2016) . Incidence rates of cataract, macular oedema, increased IOP, and reduced VA were higher with DEX than ranibizumab. Other events, including eye pain, conjunctivitis, headache, and hypertension, occurred more frequently with ranibizumab than DEX. The incidence of serious TEAEs was slightly higher with ranibizumab than DEX, but no serious TEAE occurred in more than one patient.
We identified no new safety worries during the COMRADE extension study. Incidence rates of ocular TEAEs in the study eye were higher with DEX than ranibizumab in BRVO patients (62.5% versus 55.8%) and vice versa in CRVO patients (59.1% versus 65.6%). Treatment-emergent adverse events (TEAEs) occurring more often with DEX than ranibizumab included increased IOP in both indications, conjunctival haemorrhage and cataract formation in BRVO patients. These findings are in line with the known safety profile of DEX implants, as reported in the summary of product characteristics (SmPC) (EMA 2010) and in other trials and case reports (Haller et al. 2010 (Haller et al. , 2011 Higham et al. 2016) . Treatment-emergent adverse event (TEAEs) that were reported more frequently for ranibizumab included relapse of macular oedema in both indications, eye pain in BRVO patients, and reduced VA in CRVO patients. Eye pain and reduced VA are known side effects of ranibizumab injections, as reported in the SmPC (EMA 2014). The higher incidence of relapses of macular oedema for ranibizumab can be explained by the observation that more DEX patients (BRVO: 85.0%, CRVO: 77.3%) than ranibizumab patients (BRVO: 54.9%, CRVO: 39.3%) joined the extension trial with macular oedema still present ( Table 1 ), meaning that a new TEAE of macular oedema was more likely to be documented for patients treated with ranibizumab. An increase in IOP ≥21 mmHg throughout the study period was more likely to occur with DEX than ranibizumab, which is the most relevant finding. There was no difference between treatments with regard to cataract formation over the course of 12 months. Cataract formation was graded by the investigator as being stable or deteriorated without further documentation although unlikely mild cataract formation in the DEX group could have influenced the visual results in DEX-treated patients.
The current results provide supportive evidence that maintaining VA gains in ranibizumab-treated RVO patients does not require monthly injections. During the PRN phase, the vast majority of ranibizumab-treated patients received at least one reinjection (96% (BRVO) and 80% (CRVO); mean 4.5 injections). In contrast, the majority of DEX patients underwent no retreatment, and 40% (BRVO)/46% (CRVO) of patients received one reinjection (mean 0.4 injections). These differences were to be expected, as ranibizumab was allowed to be administered monthly, whereas DEX was supposed to be administered after 6 months according to the European label (EMA 2010). Several investigators have suggested that retreatment with a DEX intravitreal implant may be required after 4-6 months (BEVOR-DEX study (Gillies et al. 2014; FraserBell et al. 2016) ). However, the risks and benefits of a short-interval retreatment with DEX are now being investigated (COMO and COBALT studies).
The design of the COMRADE extension trial has several limitations. Only a smaller proportion of CRVO and BRVO patients who completed the core studies were enrolled in the extension trial, and those individuals presenting greater BCVA improvements from baseline to month 6 were more likely to participate, indicating the possibility of selection bias as shown in Fig. 2 , and equivalently for CSRT as shown in Fig. 3 . This could also be the reason for the surprising finding that more than the half of DEX patients required a single implant over the 12-month period. Therefore, these results must be interpreted with caution. Ranibizumab revealed a better safety profile and produced greater average BCVA gains compared with the DEX implant. Long-term treatment with ranibizumab in patients with RVO does not require monthly injections, but close follow-ups and continuous treatment are essential to maintain visual improvement.
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